Clinical Trial Detail

NCT ID NCT01363817
Title Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements no
Sponsors Bristol-Myers Squibb
Indications

lymphoma

T-cell adult acute lymphocytic leukemia

Therapies

Dexamethasone

BMS-906024

Age Groups: adult

No variant requirements are available.